For the therapy of melanoma, they include ipilimumab, a monoclonal antibody directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor, and nivolumab or pembrolizumab, antibodies targeting programmed cell death-1 (PD-1) receptor (1–3). The gene discussed is PDCD1; the disease is melanoma.